The financials
Monte Rosa Therapeutics, Inc. by the numbers
Monte Rosa Therapeutics, Inc. (GLUE) reported revenue of $9.0M in Q2 2026 (quarter ended June 30, 2026), down 61% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $124M (+64% year on year) and net income −$39M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $9.0M | $23M | −61% |
| Operating income | −$49M | −$16M | n/a |
| Net income | −$43M | −$12M | n/a |
| Diluted EPS | −$0.43 | −$0.15 | n/a |